<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815086</url>
  </required_header>
  <id_info>
    <org_study_id>IND 100472</org_study_id>
    <secondary_id>1R01FD003420-01A1</secondary_id>
    <nct_id>NCT01815086</nct_id>
  </id_info>
  <brief_title>Radioimmunoimaging of Light Chain (AL) Amyloidosis</brief_title>
  <official_title>Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody (mAb) Murine (Mu) 11-F4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive
      monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by
      PET/CT imaging in patients with AL amyloidosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To be eligible for this study, patients must have a confirmed diagnosis of AL amyloidosis
      without significant cardiac (New York Heart Association class IV) disease and not be on
      kidney dialysis. Additionally, after testing, their blood must not contain antibodies to
      mouse proteins. The study requires an intravenous infusion, given over 10 minutes, of the
      radiolabeled antibody, followed 48 hours later by a PET/CT scan. A repeat scan is done 5 days
      after infusion of the antibody. A 5-ml blood specimen needs to be furnished 4 and 8 weeks
      after the antibody infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the capability of a radiolabeled amyloid-reactive monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by PET/CT in up to 30 patients with AL amyloidosis.</measure>
    <time_frame>Five days post PET/CT scan</time_frame>
    <description>PET/CT images will be taken 2 and 5 days post-radiolabeled antibody infusion to evaluate if there is organ/tissue uptake (greater than blood pool) and to determine if the presence of radiolabeled antibody correlates with clinically proven amyloid deposition.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>AL Amyloidosis</condition>
  <arm_group>
    <arm_group_label>124I-labeled anti-amyloid mAb 11-1F4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>124I-labeled anti-amyloid mAb 11-1F4 will be infused on day 0. Two and 5 days later, PET/CT scans will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)</intervention_name>
    <description>Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)</description>
    <arm_group_label>124I-labeled anti-amyloid mAb 11-1F4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a confirmed diagnosis of AL amyloidosis.

        Exclusion Criteria:

          -  New York Heart Association class IV

          -  On renal dialysis

          -  Serum antibodies to mouse protein
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2013</study_first_submitted>
  <study_first_submitted_qc>March 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2013</study_first_posted>
  <last_update_submitted>September 17, 2013</last_update_submitted>
  <last_update_submitted_qc>September 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>FDA Office of Orphan Products Development</investigator_affiliation>
    <investigator_full_name>Alan Solomon</investigator_full_name>
    <investigator_title>Professor of Mediciine; Head, Human Immunology &amp; Cancer Program</investigator_title>
  </responsible_party>
  <keyword>Radioimmunoimaging</keyword>
  <keyword>AL Amyloidosis</keyword>
  <keyword>PET/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

